Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection

Permanent URI for this collectionhttps://hdl.handle.net/11147/7148

Browse

Filters

20232

Settings

COAR Access Rights: search.filters.coarAccessRights.metadata only accessSubject: search.filters.subject.Plasmonics

Search Results

Now showing 1 - 2 of 2
  • Conference Object
    Citation - WoS: 1
    Plasmonic Functional Assay Platform for Measuring Single Cell Growth through Refractive Index Sensing
    (Optical Society of America, 2023) Avci, M.B.; Topkaya, S.N.; Yalcin-Ozuysal, O.; Khademhosseini, A.; Çetin, A.E.
    Measuring cell growth on adhesive substrates is critical for understanding cell biophysical properties and drug response. Traditional optical techniques have low sensitivity and vary in reliability depending on cell type, while microfluidic technologies rely on cell suspension. In this study, a new platform has been developed that is able to measure the weight and growth of individual cells in real−time. The platform can determine the growth rates of cells in just 10 minutes and map the growth of cell populations in short intervals. It can also identify differences in the growth of different subpopulations within a larger group. The platform was used to study the growth of MCF−7 cells and the impact of two intracellular metabolic processes on cell proliferation. The platform demonstrated the negative effect of serum starvation on cell growth and the role of a particular enzyme, ornithine decarboxylase (ODC), in cell proliferation. It was also able to show the ability of an external factor, putrescine, to rescue cells from the inhibitory effects of low osmolarity. In addition to measuring intracellular processes, the platform can determine the response of cancer cells to drug treatment. It showed the susceptibility of MCF−7 cells to a particular drug, difluoromethylornithine (DFMO), and the ability of a resistant subpopulation to survive in the presence of the drug. The platform’s ability to quickly measure cell growth in small samples makes it a potential tool for both research and clinical use. © 2023 SPIE.
  • Article
    Citation - WoS: 2
    Citation - Scopus: 2
    Plasmonic Functional Assay Platform Determines the Therapeutic Profile of Cancer Cells
    (American Chemical Society, 2023) Çetin, Arif E.; Topkaya, Seda Nur; Yazıcı, Ziya Ata; Yalçın Özuysal, Özden
    Functional assay platforms could identify the biophysicalpropertiesof cells and their therapeutic response to drug treatments. Despitetheir strong ability to assess cellular pathways, functional assaysrequire large tissue samples, long-term cell culture, and bulk measurements.Even though such a drawback is still valid, these limitations didnot hinder the interest in these platforms for their capacity to revealdrug susceptibility. Some of the limitations could be overcome withsingle-cell functional assays by identifying subpopulations usingsmall sample volumes. Along this direction, in this article, we developeda high-throughput plasmonic functional assay platform to identifythe growth profile of cells and their therapeutic profile under therapiesusing mass and growth rate statistics of individual cells. Our technologycould determine populations' growth profiles using the growthrate data of multiple single cells of the same population. Evaluatingspectral variations based on the plasmonic diffraction field intensityimages in real time, we could simultaneously monitor the mass changefor the cells within the field of view of a camera with the capacityof > & SIM;500 cells/h scanning rate. Our technology could determinethe therapeutic profile of cells under cancer drugs within few hours,while the classical techniques require days to show reduction in viabilitydue to antitumor effects. The platform could reveal the heterogeneitywithin the therapeutic profile of populations and determine subpopulationsshowing resistance to drug therapies. As a proof-of-principle demonstration,we studied the growth profile of MCF-7 cells and their therapeuticbehavior to standard-of-care drugs that have antitumor effects asshown in the literature, including difluoromethylornithine (DFMO),5-fluorouracil (5-FU), paclitaxel (PTX), and doxorubicin (Dox). Wesuccessfully demonstrated the resistant behavior of an MCF-7 variantthat could survive in the presence of DFMO. More importantly, we couldprecisely identify synergic and antagonistic effects of drug combinationsbased on the order of use in cancer therapy. Rapidly assessing thetherapeutic profile of cancer cells, our plasmonic functional assayplatform could be used to reveal personalized drug therapies for cancerpatients.